Bonitobio
28 employees on LinkedIn · 2 known investors
Bonito is building a platform for programmable oligonucleotide delivery, combining giga-scale encoded libraries with functional live-cell selections to generate proprietary datasets for an AI-enabled discovery loop. It discovers delivery ligands and oligotherapeutics — small molecule and antibody agents paired with oligotherapeutic payloads — aimed at delivery to any cell or tissue type.
Investors · 2
Frequently asked questions
- What does Bonitobio do?
- Bonito is building a platform for programmable oligonucleotide delivery, combining giga-scale encoded libraries with functional live-cell selections to generate proprietary datasets for an AI-enabled discovery loop. It discovers delivery ligands and oligotherapeutics — small molecule and antibody agents paired with oligotherapeutic payloads — aimed at delivery to any cell or tissue type.
- Who are Bonitobio's investors?
- Bonitobio's investors include JAZZ Venture Partners, Lightstone Ventures.